Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research

Seaport Therapeutics celebrates its first day on the Nasdaq (Credit: Seaport Therapeutics) May 1, 2026 12:50 PM EDTUpdated 01:12 PM PeopleFinancingR&D Q&A: Sea­port CEO and CSO on learn­ing from Karuna and the fu­ture of CNS re­search Max Gelman Senior Editor Sea­port Ther­a­peu­tics be­gan trad­ing as a pub­lic com­pa­ny on Fri­day af­ter ex­ec­u­tives rang the Nas­daq’s open­ing bell. Shares rose $SP­TX more than 20%. With a … Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER